Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Nyxoah ( (NYXH) ) has issued an announcement.
On November 13, 2025, Nyxoah announced its unaudited third-quarter results for 2025, highlighting significant developments in its clinical trials and commercialization efforts. The company reported the successful completion of its DREAM IDE trial, which met its primary endpoints and received FDA approval for the Genio system on August 8, 2025. Additionally, Nyxoah closed patient enrollment for the ACCCESS U.S. IDE study, believing the current data will suffice for statistical significance. The company also expanded its European and Middle Eastern market presence, generating revenue in countries like Germany, Switzerland, and the UK, and securing reimbursement in several regions.
The most recent analyst rating on (NYXH) stock is a Buy with a EUR10.50 price target. To see the full list of analyst forecasts on Nyxoah stock, see the NYXH Stock Forecast page.
More about Nyxoah
Nyxoah SA is a company operating in the medical technology industry, primarily focusing on developing solutions for the treatment of obstructive sleep apnea (OSA). The company’s flagship product is the Genio® system, which is designed for bilateral hypoglossal nerve stimulation to treat moderate-to-severe OSA. Nyxoah is actively involved in clinical trials and commercialization efforts, particularly in Europe and the United States, aiming to expand its market presence and secure regulatory approvals.
Average Trading Volume: 87,369
Current Market Cap: €181.5M
See more insights into NYXH stock on TipRanks’ Stock Analysis page.